Company News
AstraZeneca Elecoglipron Enters Phase III, 11.8% Loss
AstraZeneca announced its oral GLP‑1 agonist elecoglipron will move into Phase III trials after strong Phase IIb results.
In the VISTA trial, 75 mg elecoglipron produced an 11.8% average weight reduct
